Tesofensine vs Cardiogen
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineAnti-Aging & Longevity
Cardiogen- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- Short (minutes); gene-regulatory effects persist longer
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Stacks With
- —
- —